IL‐17A
is a pertinent therapeutic target for moderate to severe hidradenitis suppurativa: combined results from a pre‐clinical and Phase
II
proof‐of‐concept study
IL‐17A
is a pertinent therapeutic target for moderate to severe hidradenitis suppurativa: combined results from a pre‐clinical and Phase
II
proof‐of‐concept study
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started